ATTR-CM Treatment: Recent Updates
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
By:
Summary
In this episode, Drs. Ahmad Masri and Kevin Alexander review emerging clinical data in transthyretin amyloid cardiomyopathy (ATTR-CM) presented at the Heart Failure Society of America Annual Scientific Meeting and the American Heart Association Scientific Sessions 2025, including key findings from the ATTRibute-CM and HELIOS-B trials. The discussion highlights recent publications evaluating currently available disease-modifying therapies. Drs. Masri and Alexander translate these new data into practical insights for clinicians, focusing on how evolving evidence may influence treatment selection, therapeutic sequencing, and integration of disease-modifying therapies into everyday clinical practice.
adbl_web_anon_alc_button_suppression_c
No reviews yet